高级检索
当前位置: 首页 > 详情页

Short-and long-term outcomes and cost-effectiveness of roboticassisted versus laparoscopic liver resection for Barcelona Clinic Liver Cancer (BCLC) 0/A hepatocellular carcinoma: a multicenter propensity score-matched analysis

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Huazhong Univ Sci & Technol, Tongji Hosp, Dept Hepat Surg, Tongji Med Coll, 1095 Jiefang Ave, Wuhan 430030, Peoples R China [2]Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Ultrasound Med, Hangzhou, Peoples R China [3]Sichuan Univ, West China Hosp, Dept Gen Surg, Chengdu, Peoples R China [4]Guangdong Med Univ, Zhongshan Peoples Hosp, Dept Hepat Surg, Zhongshan, Peoples R China [5]Fujian Med Univ, Affiliated Hosp 1, Dept Hepatopancreatobiliary Surg, Fuzhou, Peoples R China [6]Gen Hosp Cent Theater Command, Dept Gen Surg, Wuhan, Peoples R China [7]Wuhan Univ, Zhongnan Hosp, Dept Neurosurg, Wuhan, Peoples R China [8]Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Clin Ctr Human Gene Res, Wuhan, Peoples R China [9]Shenzhen Peoples Hosp, Dept Hepatobiliary Surg, Shenzhen, Peoples R China [10]Tianjin Med Univ, Tianjin Cent Hosp 1, Dept Hepatobiliary Surg, Tianjin, Peoples R China [11]First Peoples Hosp Foshan, Dept Hepat Biliary Pancreat Surg, Foshan, Peoples R China [12]Hubei Polytech Univ, Huangshi Cent Hosp, Dept Hepatobiliary & Pancreat Surg, Huangshi, Peoples R China [13]Taihe Hosp, Dept Hepatobiliary Pancreat Surg, Shiyan, Peoples R China [14]Wuhan Univ, Renmin Hosp, Dept Hepatobiliary Surg, Wuhan, Peoples R China [15]Kunming Med Univ, Affiliated Hosp 1, Dept Organ Transplantat, Kunming, Peoples R China [16]Hubei Univ Arts & Sci, Xiangyang Cent Hosp, Affiliated Hosp, Dept Hepatobiliary Surg, Xiangyang, Peoples R China [17]Jingzhou Cent Hosp, Dept Hepatobiliary Surg, Jingzhou, Peoples R China [18]Shenzhen Baoan Dist Peoples Hosp, Dept Sci & Educ, Shenzhen, Peoples R China [19]Shenzhen Longhua Dist Peoples Hosp, Dept Hepatobiliary & Pancreat Surg, Shenzhen, Peoples R China [20]Qinghai Univ, Affiliated Hosp, Dept Hepatobiliary Surg, Xining, Peoples R China [21]Shaoyang Univ, Affiliated Hosp 1, Dept Gen Surg, Shaoyang, Peoples R China [22]Bazhong Cent Hosp, Dept Hepatobiliary & Pancreat Surg, Bazhong, Peoples R China [23]Guilin Med Univ, Affiliated Hosp, Dept Hepatobiliary & Pancreat Surg, Guilin, Peoples R China [24]Xiaogan Cent Hosp, Dept Hepatobiliary Surg, Xiaogan, Peoples R China
出处:
ISSN:

关键词: Hepatocellular carcinoma (HCC) recurrence pattern cost-effectiveness analysis (CEA) minimally invasive surgery liver resection

摘要:
Background: The application of robotic-assisted liver resection (RALR) in hepatocellular carcinoma (HCC) has been steadily increasing, but comprehensive comparative data with laparoscopic liver resection (LLR) remain limited. This study aims to systematically evaluate the short-and long-term outcomes, recurrence patterns, quality of life (QoL), and cost-effectiveness of RALR versus LLR for Barcelona Clinic Liver Cancer (BCLC) stage 0/A HCC. Methods: A multicenter propensity score-matched analysis was conducted using long-term follow-up data from 24 national centers, including 1,761 patients with BCLC stage 0/A HCC who underwent RALR or LLR. Prognostic indicators such as overall survival (OS) and recurrence-free survival (RFS) were analyzed, along with cost-effectiveness measures, including quality-adjusted life years (QALYs) and incremental cost effectiveness ratios (ICERs). Variables such as surgical costs, recurrence treatment costs, and QoL were meticulously recorded at different time intervals. Cox proportional hazards regression was used to assess factors influencing prognosis. Results: RALR demonstrated comparable OS and RFS rates to LLR but exhibited differences in complication profiles and recurrence patterns. Although RALR had higher initial surgical costs, it showed significant long-term economic advantages due to reduced recurrence-related and complication-related expenses, as well as improved QALY. At lower willingness-to-pay (WTP) thresholds, LLR demonstrated better cost-effectiveness. However, RALR displayed greater advantages at higher thresholds. Conclusions: This study provides robust evidence supporting the use of both RALR and LLR for patients with BCLC stage 0/A HCC, highlighting their clinical and economic benefits. While RALR may involve higher initial costs, it remains a highly cost-effective option and has the potential for broader adoption as initial costs decrease. These findings emphasize the value of minimally invasive approaches in improving long-term outcomes and optimizing healthcare resource utilization, particularly in resource-limited settings.

基金:
语种:
WOS:
中科院(CAS)分区:
出版当年[2026]版:
最新[2025]版:
大类 | 1 区 医学
小类 | 1 区 胃肠肝病学 1 区 营养学 1 区 外科
JCR分区:
出版当年[2025]版:
最新[2024]版:
Q1 GASTROENTEROLOGY & HEPATOLOGY Q1 NUTRITION & DIETETICS Q1 SURGERY

影响因子: 最新[2024版] 最新五年平均 出版当年[2025版] 出版当年五年平均 出版前一年[2024版]

第一作者:
第一作者机构: [1]Huazhong Univ Sci & Technol, Tongji Hosp, Dept Hepat Surg, Tongji Med Coll, 1095 Jiefang Ave, Wuhan 430030, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:70796 今日访问量:0 总访问量:2273 更新日期:2025-12-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司